Clinical Trials Logo

Clinical Trial Summary

Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis.

This study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Breast Neoplasms
  • Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women

NCT number NCT00171704
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date April 2005
Completion date March 2011